Institut Francais De Recherche Pour L'exploitation De La Mer (ifremer)

Université René Descartes Paris 5

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Centre Hospitalier Universitaire De Nantes

Université Paris Descartes

Nantes Université

Institut Francais De Recherche Pour L'exploitation De La Mer

Inserm

Jacqueline Ratiskol

Sylvia Colliec-Jouault

Corinne Sinquin

Jean Guezennec

Pierre Weiss

Karim Senni

Gaston-Jacques Godeau

Farida Gueniche

Myriam Yousfi

Florence Fioretti

Gérard Raguenes

Anthony Courtois

Dominique Heymann

Anne-Marie Fischer

Dominique Helley

Claire Boisset

Carmen Ruiz-Velasco

Julie Chesneau

Sabine Matou

Emilie Rederstorff

Christophe Merceron

Jérome Guicheux

Miriam Yousfi

Gerard Raguenes

Jerome Guicheux

Farida Geuniche

The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof

The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerization of said native EPSs followed by a step of sulphating the resulting depolymerized derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 &#x3bc;g (m) g/ml.

Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration

The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 &#x3bc;g (m) g/ml.

Sulfated depolymerized derivatives of expolysaccharides (EPS) from mesophilic marine bacteria, method for preparing the same, and uses thereof in tissue regeneration

The invention relates to the use of certain low-molecular weight highly sulphated polysaccharide derivatives obtained from a bacterial polysaccharide for preparing a pharmaceutical composition suitable for modulating angiogenesis, particularly for use in accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries.

Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis

Growing community of inventors

Sainte Luce sur Loire, France

Jacqueline Ratiskol